BG105715A - Combination chemotherapy - Google Patents

Combination chemotherapy

Info

Publication number: BG105715A
Authority: BG; Bulgaria
Prior art keywords: combination chemotherapy; combination; paclitaxel; meanings; substituents
Prior art date: 1998-12-22

Application number

BG105715A

Other languages

Bulgarian (bg)

English (en)

Inventor

Richard Gowan

- LEOPOLD Judith SEBOLT

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-22

Filing date

2001-07-18

Publication date

2002-04-30

2001-07-18 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

2002-04-30 Publication of BG105715A publication Critical patent/BG105715A/xx

Links

238000009096 combination chemotherapy Methods 0.000 title 1
229940124647 MEK inhibitor Drugs 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
230000000394 mitotic effect Effects 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
-1 phenyl amine compound Chemical class 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Seasonings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG105715A 1998-12-22 2001-07-18 Combination chemotherapy BG105715A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11329198P	1998-12-22	1998-12-22
US16478899P	1999-11-10	1999-11-10
PCT/US1999/030485 WO2000037141A1 (en)	1998-12-22	1999-12-21	Combination chemotherapy

Publications (1)

Publication Number	Publication Date
BG105715A true BG105715A (en)	2002-04-30

Family

ID=26810891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105715A BG105715A (en)	1998-12-22	2001-07-18	Combination chemotherapy

Country Status (31)

Country	Link
EP (1)	EP1140291B1 (cs)
JP (1)	JP2002532570A (cs)
KR (1)	KR20010099877A (cs)
CN (1)	CN1333698A (cs)
AP (1)	AP2001002175A0 (cs)
AT (1)	ATE310567T1 (cs)
AU (1)	AU2203900A (cs)
BG (1)	BG105715A (cs)
BR (1)	BR9916839A (cs)
CA (1)	CA2352326A1 (cs)
CZ (1)	CZ20012139A3 (cs)
DE (1)	DE69928568T2 (cs)
EA (1)	EA200100687A1 (cs)
EE (1)	EE200100339A (cs)
ES (1)	ES2253928T3 (cs)
GE (1)	GEP20043172B (cs)
HK (1)	HK1042057A1 (cs)
HR (1)	HRP20010473A2 (cs)
HU (1)	HUP0104844A3 (cs)
ID (1)	ID30250A (cs)
IL (1)	IL143939A0 (cs)
IS (1)	IS5969A (cs)
MA (1)	MA26768A1 (cs)
NO (1)	NO20013099L (cs)
NZ (1)	NZ512859A (cs)
OA (1)	OA11733A (cs)
PL (1)	PL348326A1 (cs)
SK (1)	SK8712001A3 (cs)
TR (1)	TR200101871T2 (cs)
WO (1)	WO2000037141A1 (cs)
YU (1)	YU45401A (cs)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en)	2010-02-25	2011-09-01	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3811775B2 (ja)	2000-07-19	2006-08-23	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
EP1365796A2 (en)	2000-09-01	2003-12-03	Van Andel Institute	Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
AU2002255852B2 (en) *	2001-03-22	2006-11-09	Van Andel Research Institute	Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en)	2001-05-09	2002-11-10	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) *	2001-07-02	2003-05-14	Warner-Lambert Company	Kombinační chemoterapie
EP1676837A4 (en) *	2003-10-08	2008-09-10	Teijin Pharma Ltd	METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND
NZ546011A (en)	2003-10-21	2009-09-25	Warner Lambert Co	Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
ZA200703912B (en)	2004-10-20	2008-09-25	Serono Lab	3-arylamino pyridine derivatives
CN1807413B (zh) *	2005-09-28	2010-05-05	中国医学科学院医药生物技术研究所	咔唑磺酰胺衍生物及其制备方法
SI1934174T1 (sl)	2005-10-07	2011-08-31	Exelixis Inc	Inhibitorji MEK in postopki za njihovo uporabo
WO2007054556A1 (de)	2005-11-11	2007-05-18	Æterna Zentaris Gmbh	Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US8217042B2 (en)	2005-11-11	2012-07-10	Zentaris Gmbh	Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de)	2005-11-11	2007-05-30	Zentaris GmbH	Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
PL2101759T3 (pl)	2006-12-14	2019-05-31	Exelixis Inc	Sposoby stosowania inhibitorów MEK
BR112012022801B8 (pt)	2010-03-09	2019-10-29	Dana Farber Cancer Inst Inc	método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CN103301096B (zh) *	2012-03-14	2015-05-06	中国中化股份有限公司	取代二苯胺类化合物作为制备抗肿瘤药物的应用
KR102204520B1 (ko)	2012-10-12	2021-01-20	엑셀리시스, 인코포레이티드	암의 치료에 사용하기 위한 화합물의 신규 제조 방법
JP6465790B2 (ja) *	2013-02-27	2019-02-06	第一三共株式会社	Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CN105384754B (zh) *	2014-09-02	2018-04-20	上海科州药物研发有限公司	作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) *	2020-08-06	2022-12-06	湖北省生物农药工程研究中心	基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1997032604A1 (en) *	1996-03-07	1997-09-12	Novartis Ag	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU5610398A (en) *	1997-02-28	1998-09-18	Warner-Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
CA2284685A1 (en) *	1997-03-21	1998-10-01	Board Of Regents, The University Of Texas System	Noey2 gene compositions and methods of use
US6002008A (en) *	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6040321A (en) *	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) *	1998-11-20	1999-09-28	Isis Pharmaceuticals, Inc.	Antisense modulation of MEK2 expression

1999
- 1999-12-21 AP APAP/P/2001/002175A patent/AP2001002175A0/en unknown
- 1999-12-21 IL IL14393999A patent/IL143939A0/xx unknown
- 1999-12-21 CN CN99815040A patent/CN1333698A/zh active Pending
- 1999-12-21 HK HK02103397.1A patent/HK1042057A1/zh unknown
- 1999-12-21 KR KR1020017007874A patent/KR20010099877A/ko not_active Withdrawn
- 1999-12-21 WO PCT/US1999/030485 patent/WO2000037141A1/en not_active Ceased
- 1999-12-21 HU HU0104844A patent/HUP0104844A3/hu unknown
- 1999-12-21 CZ CZ20012139A patent/CZ20012139A3/cs unknown
- 1999-12-21 TR TR2001/01871T patent/TR200101871T2/xx unknown
- 1999-12-21 DE DE69928568T patent/DE69928568T2/de not_active Expired - Fee Related
- 1999-12-21 HR HR20010473A patent/HRP20010473A2/hr not_active Application Discontinuation
- 1999-12-21 AT AT99966523T patent/ATE310567T1/de not_active IP Right Cessation
- 1999-12-21 BR BR9916839-1A patent/BR9916839A/pt not_active Application Discontinuation
- 1999-12-21 SK SK871-2001A patent/SK8712001A3/sk unknown
- 1999-12-21 OA OA1200100161A patent/OA11733A/en unknown
- 1999-12-21 GE GEAP19996007A patent/GEP20043172B/en unknown
- 1999-12-21 EP EP99966523A patent/EP1140291B1/en not_active Expired - Lifetime
- 1999-12-21 AU AU22039/00A patent/AU2203900A/en not_active Abandoned
- 1999-12-21 JP JP2000589248A patent/JP2002532570A/ja active Pending
- 1999-12-21 ID IDW00200101616A patent/ID30250A/id unknown
- 1999-12-21 EA EA200100687A patent/EA200100687A1/ru unknown
- 1999-12-21 CA CA002352326A patent/CA2352326A1/en not_active Abandoned
- 1999-12-21 NZ NZ512859A patent/NZ512859A/en unknown
- 1999-12-21 PL PL99348326A patent/PL348326A1/xx not_active Application Discontinuation
- 1999-12-21 EE EEP200100339A patent/EE200100339A/xx unknown
- 1999-12-21 ES ES99966523T patent/ES2253928T3/es not_active Expired - Lifetime
- 1999-12-21 YU YU45401A patent/YU45401A/sh unknown
2001
- 2001-06-14 IS IS5969A patent/IS5969A/is unknown
- 2001-06-21 NO NO20013099A patent/NO20013099L/no not_active Application Discontinuation
- 2001-07-18 BG BG105715A patent/BG105715A/xx unknown
- 2001-07-19 MA MA26275A patent/MA26768A1/fr unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en)	2010-02-25	2011-09-01	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en)	2010-02-25	2016-06-08	Dana-Farber Cancer Institute, Inc.	Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number	Publication date
HK1042057A1 (zh)	2002-08-02
AP2001002175A0 (en)	2001-06-21
WO2000037141A1 (en)	2000-06-29
HRP20010473A2 (en)	2002-08-31
NO20013099D0 (no)	2001-06-21
EP1140291B1 (en)	2005-11-23
ATE310567T1 (de)	2005-12-15
NO20013099L (no)	2001-08-20
AU2203900A (en)	2000-07-12
JP2002532570A (ja)	2002-10-02
IS5969A (is)	2001-06-14
EP1140291A1 (en)	2001-10-10
EE200100339A (et)	2002-10-15
PL348326A1 (en)	2002-05-20
TR200101871T2 (tr)	2001-10-22
YU45401A (sh)	2004-07-15
BR9916839A (pt)	2001-10-09
HUP0104844A3 (en)	2003-05-28
CZ20012139A3 (cs)	2002-01-16
KR20010099877A (ko)	2001-11-09
DE69928568T2 (de)	2006-07-27
MA26768A1 (fr)	2004-12-20
IL143939A0 (en)	2002-04-21
OA11733A (en)	2005-05-12
DE69928568D1 (de)	2005-12-29
NZ512859A (en)	2004-06-25
SK8712001A3 (en)	2002-02-05
ID30250A (id)	2001-11-15
CN1333698A (zh)	2002-01-30
GEP20043172B (en)	2004-02-25
HUP0104844A2 (en)	2002-06-29
EA200100687A1 (ru)	2001-12-24
CA2352326A1 (en)	2000-06-29
ES2253928T3 (es)	2006-06-01
WO2000037141A9 (en)	2000-12-07

Publication	Publication Date	Title
BG105715A (en)	2002-04-30	Combination chemotherapy
BG105369A (en)	2001-12-29	Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
AP2001002103A0 (en)	2001-03-31	Substituted phenyl derivatives, their preparation and use.
DE69713402D1 (de)	2002-07-18	Liganden des neuropeptids y
MY132094A (en)	2007-09-28	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
GEP20074185B (en)	2007-08-10	Incclusion complexs of aryl- heterocyclic salts
BG103413A (en)	2000-02-29	Derivatives of sulphinic acid, their production and application
AU3110999A (en)	1999-10-18	Disubstituted pyrazolines and triazolines as factor xa inhibitors
EP1277754B8 (en)	2005-09-28	Imidazopyridine derivatives
GEP20084500B (en)	2008-10-10	Heterocyclocarboxamide derivatives
ID29076A (id)	2001-07-26	Kombinasi senyawa aktif fungisida
YU39803A (sh)	2006-05-25	Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
ZA200005161B (en)	2001-09-26	Anti-inflammatory, antibacterial benzyl phenol agents.
CY2509B1 (en)	2005-12-23	New thiazole derivatives with phosphodiesterase-inhibitting effect
PL341239A1 (en)	2001-03-26	Dihydrobenzofuranes
MX9708827A (es)	1998-02-28	Derivados novedosos de amidina utiles como inhibidores de agregacion plaquetaria y como vasodilatadores.
AU7259701A (en)	2002-01-14	Coumarin derivatives with comt inhibiting activity
MY136297A (en)	2008-09-30	Piperazine derivatives having sst1 antagonistic activity
MY128164A (en)	2007-01-31	Compounds
YU83100A (sh)	2003-04-30	Fkbp inhibitori
BG105964A (en)	2002-08-30	C(10) carbonate substituted taxanes and their use as antitumor agents
MXPA05006957A (es)	2005-09-30	Nuevos derivados de fosforamida.
WO2000035428A3 (de)	2000-09-28	Tricyclische stickstoffheterocyclen als pde iv inhibitoren
BG105965A (en)	2002-07-31	C10 ester substituted taxanes and their application as antitumor agents
MY119841A (en)	2005-07-29	Cephalosporines having cyclic aminoguanidine substituents as antibiotics.